However, the "off target" effects of PPARγ agonists [44,45], the dual role that some ligands play when they are applied to the cells at different concentrations [46], and the paradoxical anti-cancer effect of PPARγ antagonists [47] necessitated the use of other approaches to evaluate the consequences of PPARγ transactivation in cancer. Here, PPARG is linked to cancer.